These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L; Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546 [TBL] [Abstract][Full Text] [Related]
30. Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease. Fayek SA; Beshears E; Lieber R; Alvey N; Sauer A; Poirier J; Hollinger EF; Olaitan OK; Jensik S; Geyston J; Brokhof MM; Hodowanec AC; Hertl M; Simon DM Transplant Proc; 2016; 48(6):2056-2064.e1. PubMed ID: 27569944 [TBL] [Abstract][Full Text] [Related]
31. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients. Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246 [TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus infection in heart transplantation: A single center experience. Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266 [TBL] [Abstract][Full Text] [Related]
33. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience. Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027 [TBL] [Abstract][Full Text] [Related]
34. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. Merigan TC; Renlund DG; Keay S; Bristow MR; Starnes V; O'Connell JB; Resta S; Dunn D; Gamberg P; Ratkovec RM N Engl J Med; 1992 Apr; 326(18):1182-6. PubMed ID: 1313549 [TBL] [Abstract][Full Text] [Related]
35. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients. Varga M; Rajczy K; Telkes G; Hídvégi M; Péter A; Remport A; Korbonits M; Fazakas J; Toronyi E; Sárváry E; Kóbori L; Járay J Nephrol Dial Transplant; 2008 Aug; 23(8):2673-8. PubMed ID: 18332066 [TBL] [Abstract][Full Text] [Related]
36. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients. Murray BM; Subramaniam S Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105 [TBL] [Abstract][Full Text] [Related]
38. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial. Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336 [TBL] [Abstract][Full Text] [Related]
39. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients. Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974 [TBL] [Abstract][Full Text] [Related]
40. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]